MedTrace Logo

Magnesium Treatment of Inflammation in Disorders of Glucose Homeostasis

NCT01980459 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 47

Last updated 2016-11-30

No results posted yet for this study

Summary

In most diabetic patients where low blood magnesium levels occur the important depletion of cellular levels is usually not measured. This study will measure both blood and oral mucosal cell magnesium levels before and after 3 months of supplementation with magnesium tablets (the recommended dietary amount of 336 milligrams per day). These magnesium levels will be correlated with blood levels of indicators of inflammation (eg C reactive protein) to see whether the cellular levels are more reliable than blood levels of magnesium for appropriate treatment of magnesium deficiency in diabetic patients.

Conditions

  • Non-Insulin Dependent Diabetes Mellitus

Interventions

DIETARY_SUPPLEMENT

magnesium lactate

Patient will be given 4 tablets a day of study supplement (Magnesium Lactate) for 3 months. Magnesium cellular and serum levels will be compared prior and post intervention.

Sponsors & Collaborators

  • Nadia Zghoul, PhD, Dept of Clinical Research

    collaborator UNKNOWN

  • Dasman Diabetes Institute

    collaborator OTHER

  • George Washington University

    lead OTHER

Principal Investigators

  • William B Weglicki, MD · George Washington University

  • Nadia Zghoul, PhD · Dasmin Diabetes Institute

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-10-31
Primary Completion
2016-07-31
Completion
2016-07-31

Countries

  • Kuwait

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01980459 on ClinicalTrials.gov